![Novartis dans la barre de recherche](/sites/default/files/styles/172x172/public/2023-05/Novartis_risque%20de%20confusion.jpg?itok=a71JTFI0)
News & opinion
EU General Court finds no risk of confusion in pharmaceutical trademark dispute
In disputes over pharmaceutical trademarks, the courts take a precautionary approach to exclude any risk of confusion between two medicines marketed under similar brand names. However, this restrictive approach has been qualified by EU case law, as Florence Chapin explains.